SERPINB13

Summary

SERPINB13 (serpin family B member 13, HGNC:8944) is a protein-coding gene on chromosome 18q21.33, encoding Serpin B13 (Q9UIV8). May play a role in the proliferation or differentiation of keratinocytes.

The protein encoded by this gene is a member of the serpin family of serine protease inhibitors. The encoded protein inhibits the activity of cathepsin K and is itself transcriptionally repressed by RUNX1. This gene is downregulated in many types of cancer.

Source: NCBI Gene 5275 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 62 total
• MANE Select transcript: NM_012397

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:8944
Approved symbol	SERPINB13
Name	serpin family B member 13
Location	18q21.33
Locus type	gene with protein product
Status	Approved
Aliases	HUR7
Ensembl gene	ENSG00000197641
Ensembl biotype	protein_coding
OMIM	604445
Entrez	5275

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 4 protein_coding, 1 nonsense_mediated_decay, 1 retained_intron

ENST00000269489, ENST00000344731, ENST00000415733, ENST00000431153, ENST00000438844, ENST00000479842

RefSeq mRNA: 6 — MANE Select: NM_012397 NM_001307923, NM_001348267, NM_001348268, NM_001348269, NM_001348270, NM_012397

CCDS: CCDS11985, CCDS77195

Canonical transcript exons

ENST00000344731 — 8 exons

Exon	Start	End
ENSE00000950306	63589656	63589715
ENSE00000950307	63592348	63592476
ENSE00000950308	63592854	63592971
ENSE00001923386	63596959	63599192
ENSE00001935559	63587343	63587450
ENSE00003566033	63588651	63588832
ENSE00003598818	63594355	63594497
ENSE00003659575	63595029	63595184

Expression profiles

Bgee: expression breadth ubiquitous, 149 present calls, max score 99.56.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 2.5554 / max 1144.3197, expressed in 102 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
170589	1.7862	87
170588	0.4688	60
170587	0.1868	52
208581	0.0522	28
170584	0.0220	6
170586	0.0143	10
170583	0.0134	6
170585	0.0116	5

Top tissues by expression

260 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
tongue squamous epithelium	UBERON:0006919	99.56	gold quality
pharyngeal mucosa	UBERON:0000355	99.44	gold quality
cervix epithelium	UBERON:0004801	99.08	gold quality
gingiva	UBERON:0001828	99.07	gold quality
oral cavity	UBERON:0000167	98.99	gold quality
gingival epithelium	UBERON:0001949	98.98	gold quality
lower esophagus mucosa	UBERON:0035834	98.88	gold quality
cervix squamous epithelium	UBERON:0006922	98.61	gold quality
buccal mucosa cell	CL:0002336	98.46	gold quality
body of tongue	UBERON:0011876	98.42	gold quality
squamous epithelium	UBERON:0006914	98.33	gold quality
esophagus squamous epithelium	UBERON:0006920	97.85	gold quality
mammalian vulva	UBERON:0000997	97.83	gold quality
esophagus mucosa	UBERON:0002469	97.71	gold quality
penis	UBERON:0000989	97.50	gold quality
epithelium of esophagus	UBERON:0001976	97.23	gold quality
tongue	UBERON:0001723	94.36	gold quality
upper leg skin	UBERON:0004262	90.44	gold quality
upper arm skin	UBERON:0004263	90.26	gold quality
vagina	UBERON:0000996	89.45	gold quality
trachea	UBERON:0003126	87.96	gold quality
superior surface of tongue	UBERON:0007371	87.87	gold quality
nasal cavity epithelium	UBERON:0005384	87.79	gold quality
amniotic fluid	UBERON:0000173	87.35	gold quality
epithelium of nasopharynx	UBERON:0001951	85.12	gold quality
nasal cavity mucosa	UBERON:0001826	84.85	gold quality
skin of abdomen	UBERON:0001416	83.58	gold quality
zone of skin	UBERON:0000014	83.47	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	83.02	gold quality
skin of leg	UBERON:0001511	82.24	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-CURD-114	yes	380.06
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): RUNX1

miRNA regulators (miRDB)

78 targeting SERPINB13, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3064-3P	100.00	70.09	1254
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420
HSA-MIR-6845-3P	99.94	66.88	1439
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-9902	99.89	69.15	2250
HSA-MIR-129-5P	99.88	70.26	3273

Literature-anchored findings (GeneRIF, showing 8)

• A novel member of the serine proteinase inhibitor (Serpin) gene family that was originally cloned from a keratinocyte cDNA library. It has specificity for inhibiting lysosomal cysteine proteinases. (PMID:12504904)
• Hurpin is a selective inhibitor of lysosomal cathepsin L and protects keratinocytes from ultraviolet-induced apoptosis. (PMID:12809493)
• hurpin is expressed in skin and has a possible role in inflammatory processes or the regulation of endogenous or pathogen-derived proteinase activity (PMID:15885077)
• Down-regulation of SERPINB13 is associated with head and neck squamous cell carcinoma (PMID:16357159)
• the expression of hurpin was confined mainly to the basal layer in normal skin samples, whereas hurpin was overexpressed and redistributed in diseased skin (PMID:16433682)
• Downregulation of SERPINB13 protein expression in HNSCC is positively associated with poor clinical outcome. Therefore, SERPINB13 seems to act as an important protease inhibitor involved in the progression of HNSCC. (PMID:19569240)
• These data demonstrate that RUNX1 is an important regulator of SERPINB13 and cathepsin K activity. (PMID:21723253)
• clade B serpins help to maintain homeostasis by inducing protective humoral immunity (PMID:22593614)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Serpinb13	ENSMUSG00000048775
rattus_norvegicus	Serpinb13	ENSRNOG00000028194

Paralogs (36): SERPINB1 (ENSG00000021355), SERPINB3 (ENSG00000057149), SERPIND1 (ENSG00000099937), SERPINA4 (ENSG00000100665), SERPINE1 (ENSG00000106366), SERPINI2 (ENSG00000114204), SERPINC1 (ENSG00000117601), SERPINA7 (ENSG00000123561), SERPINB6 (ENSG00000124570), SERPINF1 (ENSG00000132386), AGT (ENSG00000135744), SERPINE2 (ENSG00000135919), SERPINA10 (ENSG00000140093), SERPING1 (ENSG00000149131), SERPINH1 (ENSG00000149257), SERPINI1 (ENSG00000163536), SERPINA12 (ENSG00000165953), SERPINB7 (ENSG00000166396), SERPINB8 (ENSG00000166401), SERPINB12 (ENSG00000166634), SERPINF2 (ENSG00000167711), SERPINA9 (ENSG00000170054), SERPINA6 (ENSG00000170099), SERPINB9 (ENSG00000170542), SERPINA11 (ENSG00000186910), SERPINA5 (ENSG00000188488), SERPINA3 (ENSG00000196136), SERPINA1 (ENSG00000197249), SERPINB2 (ENSG00000197632), SERPINB11 (ENSG00000206072), SERPINB4 (ENSG00000206073), SERPINB5 (ENSG00000206075), HMSD (ENSG00000221887), SERPINB10 (ENSG00000242550), SERPINE3 (ENSG00000253309), SERPINA2 (ENSG00000258597)

Protein

Protein identifiers

Serpin B13 — Q9UIV8 (reviewed: Q9UIV8)

Alternative names: HaCaT UV-repressible serpin, Headpin, Peptidase inhibitor 13, Proteinase inhibitor 13

All UniProt accessions (5): A0A0A0MQW3, C9JL93, F8WE70, Q9UIV8, H7BZS9

UniProt curated annotations — full annotation on UniProt →

Function. May play a role in the proliferation or differentiation of keratinocytes.

Subcellular location. Cytoplasm.

Tissue specificity. Skin specific.

Similarity. Belongs to the serpin family. Ov-serpin subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9UIV8-1	1	yes
Q9UIV8-2	2

RefSeq proteins (6): NP_001294852, NP_001335196, NP_001335197, NP_001335198, NP_001335199, NP_036529* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000215	Serpin_fam	Family
IPR023795	Serpin_CS	Conserved_site
IPR023796	Serpin_dom	Domain
IPR036186	Serpin_sf	Homologous_superfamily
IPR042178	Serpin_sf_1	Homologous_superfamily
IPR042185	Serpin_sf_2	Homologous_superfamily

Pfam: PF00079

UniProt features (7 total): sequence conflict 3, chain 1, site 1, splice variant 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UIV8-F1	87.44	0.69

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 356–357 (reactive bond)

Function

Pathways and Gene Ontology

Reactome pathways

5 pathways

ID	Pathway
R-HSA-8939242	RUNX1 regulates transcription of genes involved in differentiation of keratinocytes
R-HSA-212436	Generic Transcription Pathway
R-HSA-73857	RNA Polymerase II Transcription
R-HSA-74160	Gene expression (Transcription)
R-HSA-8878171	Transcriptional regulation by RUNX1

MSigDB gene sets: 111 (showing top): GOBP_NEGATIVE_REGULATION_OF_PROTEOLYSIS, GOBP_REGULATION_OF_EPITHELIAL_CELL_APOPTOTIC_PROCESS, JAEGER_METASTASIS_DN, GOBP_NEGATIVE_REGULATION_OF_HYDROLASE_ACTIVITY, AMIT_SERUM_RESPONSE_20_MCF10A, ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_UP, ONDER_CDH1_TARGETS_3_DN, GOBP_REGULATION_OF_HYDROLASE_ACTIVITY, GOBP_NEGATIVE_REGULATION_OF_EPITHELIAL_CELL_APOPTOTIC_PROCESS, GOBP_REGULATION_OF_PEPTIDASE_ACTIVITY, GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION, GOBP_RESPONSE_TO_UV, GOBP_RESPONSE_TO_RADIATION, GOBP_NEGATIVE_REGULATION_OF_CATALYTIC_ACTIVITY, GOBP_NEGATIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS

GO Biological Process (4): response to UV (GO:0009411), negative regulation of endopeptidase activity (GO:0010951), regulation of proteolysis (GO:0030162), negative regulation of keratinocyte apoptotic process (GO:1902173)

GO Molecular Function (6): protease binding (GO:0002020), serine-type endopeptidase inhibitor activity (GO:0004867), cysteine-type endopeptidase inhibitor activity (GO:0004869), endopeptidase inhibitor activity (GO:0004866), protein binding (GO:0005515), peptidase inhibitor activity (GO:0030414)

GO Cellular Component (8): obsolete extracellular space (GO:0005615), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), cytosol (GO:0005829), nuclear speck (GO:0016607), lysosomal lumen (GO:0043202), extracellular exosome (GO:0070062), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-4 pathways:

Category	Pathways
Transcriptional regulation by RUNX1	1
RNA Polymerase II Transcription	1
Gene expression (Transcription)	1
Generic Transcription Pathway	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
endopeptidase activity	2
endopeptidase inhibitor activity	2
response to light stimulus	1
negative regulation of peptidase activity	1
regulation of endopeptidase activity	1
proteolysis	1
regulation of protein metabolic process	1
keratinocyte apoptotic process	1
regulation of keratinocyte apoptotic process	1
negative regulation of epithelial cell apoptotic process	1
enzyme binding	1
serine-type endopeptidase activity	1
cysteine-type endopeptidase activity	1
peptidase inhibitor activity	1
endopeptidase regulator activity	1
binding	1
enzyme inhibitor activity	1
peptidase activity	1
peptidase regulator activity	1
nuclear lumen	1
intracellular anatomical structure	1
cytoplasm	1
nuclear ribonucleoprotein granule	1
lysosome	1
vacuolar lumen	1
extracellular vesicle	1

Protein interactions and networks

STRING

760 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SERPINB13	CTSL	P07711	623
SERPINB13	KLK6	Q92876	485
SERPINB13	S100A7	P31151	482
SERPINB13	BPIFB1	Q8TDL5	478
SERPINB13	KRT6A	P02538	445
SERPINB13	S100A12	P80511	444
SERPINB13	KLK14	Q9P0G3	444
SERPINB13	KRT6B	P04259	426
SERPINB13	S100A2	P29034	426
SERPINB13	ING1	Q9UK53	418
SERPINB13	LCE2A	Q5TA79	413
SERPINB13	CSTA	P01040	412
SERPINB13	SPRR2G	Q9BYE4	407
SERPINB13	KRT77	Q7Z794	406
SERPINB13	SPRR4	Q96PI1	404

IntAct

94 interactions, top by confidence:

A	B	Type	Score
ANXA9	PPL	psi-mi:“MI:0914”(association)	0.660
POLR2L	RCCD1	psi-mi:“MI:0914”(association)	0.640
CCNC	MED19	psi-mi:“MI:0914”(association)	0.640
DLG2	SERPINB13	psi-mi:“MI:0915”(physical association)	0.560
FTH1	A2ML1	psi-mi:“MI:0914”(association)	0.530
TBC1D22B	A2ML1	psi-mi:“MI:0914”(association)	0.530
GMCL1	A2ML1	psi-mi:“MI:0914”(association)	0.530
FRMD1	A2ML1	psi-mi:“MI:0914”(association)	0.530
ACAD9	PPL	psi-mi:“MI:0914”(association)	0.530
RBM24	PPL	psi-mi:“MI:0914”(association)	0.530
ZIC1	CTSV	psi-mi:“MI:0914”(association)	0.530
GDF5	SERPINB7	psi-mi:“MI:0914”(association)	0.530
SERPINB13	TTC4	psi-mi:“MI:0914”(association)	0.530
KHDC4	TYMP	psi-mi:“MI:0914”(association)	0.530
VPS35	SPAG9	psi-mi:“MI:0914”(association)	0.530
SERPINB13	BRAF	psi-mi:“MI:2364”(proximity)	0.470
BRAF	SERPINB13	psi-mi:“MI:0915”(physical association)	0.470
TEX14	DNAJB6	psi-mi:“MI:0914”(association)	0.350
GABARAPL1		psi-mi:“MI:0914”(association)	0.350
KLHL11	PIPSL	psi-mi:“MI:0914”(association)	0.350
SRRT	A2ML1	psi-mi:“MI:0914”(association)	0.350
STX17	A2ML1	psi-mi:“MI:0914”(association)	0.350
PI4KAP1	A2ML1	psi-mi:“MI:0914”(association)	0.350
OR2A4	A2ML1	psi-mi:“MI:0914”(association)	0.350
PPP2R2B	A2ML1	psi-mi:“MI:0914”(association)	0.350
GABPA	A2ML1	psi-mi:“MI:0914”(association)	0.350
RIPPLY3	A2ML1	psi-mi:“MI:0914”(association)	0.350
STK11	A2ML1	psi-mi:“MI:0914”(association)	0.350
FCF1	SULT2B1	psi-mi:“MI:0914”(association)	0.350

BioGRID (101): SERPINB13 (Affinity Capture-MS), SERPINB13 (Affinity Capture-MS), SERPINB13 (Affinity Capture-MS), SERPINB13 (Co-fractionation), ROR1 (Affinity Capture-MS), BSDC1 (Affinity Capture-MS), BRAP (Affinity Capture-MS), C1orf198 (Affinity Capture-MS), RNF34 (Affinity Capture-MS), RBM14-RBM4 (Affinity Capture-MS), SERPINB13 (Affinity Capture-MS), C9orf78 (Affinity Capture-MS), TTC4 (Affinity Capture-MS), ADD2 (Affinity Capture-MS), SERPINB13 (Affinity Capture-MS)

ESM2 similar proteins: A0A090BX51, A2I7M9, A2I7N0, A2I7N2, A5PJK0, A9RA96, B0CMB0, B1MTB7, B1MTC3, B2KI30, B3RFC3, B4USX2, E2RVI8, O08800, O73790, O73860, O75635, P01012, P01013, P01014, P05120, P05544, P09006, P12388, P19104, P29508, P29524, P36952, P48594, P48595, P70124, P70458, P70564, Q03044, Q52L45, Q5I0S8, Q5M8J5, Q5SV42, Q6GLQ1, Q6V115

Diamond homologs: A0A090BX51, A0A0K8RCY5, A0A0K8RJ89, A0A0K8RJV9, A5PJK0, A9RA96, B0CMB0, B1MTB7, B1MTC3, B2KI30, B3RFC3, B4USX2, E2RVI8, O02739, O08800, O35684, O54757, O54758, O54759, O54760, O73790, O73860, O75635, O75830, P01008, P01011, P01012, P01014, P05120, P05619, P12388, P17475, P19104, P22323, P22325, P22922, P23035, P29508, P29524, P30740

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

62 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	57
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1021 predictions. Top by Δscore:

Variant	Effect	Δscore
18:63588830:G:GT	donor_gain	1.0000
18:63589650:TTCCA:T	acceptor_loss	1.0000
18:63589651:TCCA:T	acceptor_loss	1.0000
18:63589652:CCA:C	acceptor_loss	1.0000
18:63589653:CAGG:C	acceptor_loss	1.0000
18:63589654:A:AC	acceptor_loss	1.0000
18:63589655:G:GT	acceptor_loss	1.0000
18:63589655:GGT:G	acceptor_gain	1.0000
18:63589713:GTG:G	donor_gain	1.0000
18:63590321:GAA:G	donor_gain	1.0000
18:63592345:A:AG	acceptor_gain	1.0000
18:63592346:A:G	acceptor_gain	1.0000
18:63595025:GCAG:G	acceptor_loss	1.0000
18:63595027:A:AC	acceptor_loss	1.0000
18:63595027:A:AG	acceptor_gain	1.0000
18:63595028:G:GA	acceptor_loss	1.0000
18:63595028:G:GG	acceptor_gain	1.0000
18:63595028:GA:G	acceptor_gain	1.0000
18:63595028:GAGC:G	acceptor_gain	1.0000
18:63595028:GAGCA:G	acceptor_gain	1.0000
18:63595180:AGAAG:A	donor_loss	1.0000
18:63595182:AAG:A	donor_loss	1.0000
18:63595185:GT:G	donor_loss	1.0000
18:63595186:T:A	donor_loss	1.0000
18:63587447:CGAGG:C	donor_loss	0.9900
18:63587448:GAG:G	donor_gain	0.9900
18:63587448:GAGGT:G	donor_loss	0.9900
18:63587450:GGT:G	donor_loss	0.9900
18:63587451:G:C	donor_loss	0.9900
18:63587451:G:GG	donor_gain	0.9900

AlphaMissense

2635 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
18:63594483:T:C	F201L	0.986
18:63594485:T:A	F201L	0.986
18:63594485:T:G	F201L	0.986
18:63594453:T:C	F191L	0.985
18:63594455:T:A	F191L	0.985
18:63594455:T:G	F191L	0.985
18:63594441:T:A	W187R	0.982
18:63594441:T:C	W187R	0.982
18:63597295:T:C	F370L	0.982
18:63597297:C:A	F370L	0.982
18:63597297:C:G	F370L	0.982
18:63594443:G:C	W187C	0.975
18:63594443:G:T	W187C	0.975
18:63592447:T:C	F109L	0.966
18:63592449:T:A	F109L	0.966
18:63592449:T:G	F109L	0.966
18:63594454:T:C	F191S	0.965
18:63597283:T:C	C366R	0.961
18:63592908:T:C	F137L	0.959
18:63592910:T:A	F137L	0.959
18:63592910:T:G	F137L	0.959
18:63595054:T:C	M214T	0.958
18:63594484:T:C	F201S	0.954
18:63597041:T:C	L285S	0.952
18:63596995:T:A	W270R	0.947
18:63596995:T:C	W270R	0.947
18:63594454:T:G	F191C	0.944
18:63595055:G:A	M214I	0.944
18:63595055:G:C	M214I	0.944
18:63595055:G:T	M214I	0.944

dbSNP variants (sampled 300 via entrez): RS1000016646 (18:63593372 C>T), RS1000369284 (18:63593783 T>A), RS1000862780 (18:63586325 C>T), RS1000971638 (18:63592084 G>A,T), RS1000999920 (18:63589995 TA>T), RS1001053583 (18:63590177 G>T), RS1001476501 (18:63586593 G>A), RS1001779540 (18:63586995 T>C), RS1002164351 (18:63586036 T>C), RS1002477909 (18:63585404 T>A), RS1002989159 (18:63589463 A>G), RS1003189473 (18:63598764 G>A), RS1003195653 (18:63588398 T>C), RS1003451861 (18:63589266 A>C), RS1003892632 (18:63585587 T>A)

Disease associations

OMIM: gene MIM:604445 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST004606_36	Eosinophil count	9.000000e-11
GCST004617_128	Eosinophil percentage of granulocytes	2.000000e-09
GCST004624_17	Sum eosinophil basophil counts	1.000000e-09
GCST90002381_558	Eosinophil count	3.000000e-26

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004842	eosinophil count
EFO:0007996	eosinophil percentage of granulocytes
EFO:0005090	basophil count

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

27 total (human), top 27 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases expression, decreases expression, affects cotreatment, increases abundance	3
Arsenic	affects cotreatment, decreases expression, increases abundance	2
urushiol	increases expression	1
bisphenol A	increases methylation	1
sodium arsenate	decreases expression, increases abundance	1
pyrogallol 1,3-dimethyl ether	increases expression, affects cotreatment, decreases expression, affects localization	1
cobaltous chloride	increases expression	1
cupric chloride	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	affects cotreatment, increases expression	1
CGP 52608	affects binding, increases reaction	1
Air Pollutants	decreases expression, increases abundance	1
Benzo(a)pyrene	affects methylation, decreases methylation	1
Calcitriol	decreases expression	1
Dichlorodiphenyl Dichloroethylene	decreases expression	1
Dinitrochlorobenzene	affects binding	1
Estradiol	affects cotreatment, decreases expression	1
Furaldehyde	affects cotreatment, decreases expression, affects localization, increases expression	1
Lipopolysaccharides	affects cotreatment, increases expression	1
Nickel	increases expression	1
Silicon Dioxide	decreases expression	1
Smoke	decreases expression	1
Sodium Chloride	affects cotreatment, affects localization, increases expression, decreases expression	1
Tetrachlorodibenzodioxin	increases expression	1
Tobacco Smoke Pollution	increases expression	1
Cadmium Chloride	increases expression	1
Lactic Acid	decreases expression	1
Particulate Matter	decreases expression, increases abundance	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer